Table 2 Diagnostic performance of the top 13 autoantibody markers for detecting gastric cancer.
Antigen | Training set | Validation set | |||
|---|---|---|---|---|---|
Specificity [95% CI] in % | sensitivity [95% CI] in % | Youden’s index* | specificity [95% CI] in % | sensitivity [95% CI] in % | |
MAGEA4** | 98 [95–99] | 12 [7–18] | 0.09 | 95 [88–98] | 14 [10–21] |
CTAG1** | 98 [95–99] | 11 [7–17] | 0.07 | 98 [93–99] | 9 [5–15] |
CTAG2 | 98 [95–99] | 8 [4–13] | 0.05 | 98 [93–99] | 8 [4–13] |
DDX53 | 98 [95–99] | 8 [4–13] | 0.05 | 99 [94–100] | 6 [3–11] |
TP53** | 98 [95–99] | 7 [4–12] | 0.07 | 99 [94–100] | 8 [4–13] |
MAGEA3 | 98 [95–99] | 7 [4–12] | 0.10 | 100 [96–100] | 10 [6–16] |
SDCCAG8** | 98 [95–99] | 6 [3–11] | 0.02 | 97 [91–99] | 5 [2–10] |
KLK3_iso2 | 98 [95–99] | 6 [3–11] | 0.03 | 98 [93–99] | 5 [2–10] |
ERBB2_N | 98 [95–99] | 5 [3–10] | 0.02 | 95 [88–98] | 7 [4–12] |
ERBB2_C** | 98 [95–99] | 5 [3–10] | 0.02 | 98 [93–99] | 4 [2–9] |
IGF2BP1 | 98 [95–99] | 5 [3–10] | 0.01 | 94 [87–97] | 7 [4–12] |
GRINA | 98 [95–99] | 5 [3–10] | 0.03 | 98 [93–99] | 5 [3–10] |
UBQLN1 | 98 [95–99] | 5 [3–10] | 0.02 | 97 [91–99] | 5 [2–10] |
